Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
41 hedge funds and large institutions have $229M invested in Evelo Biosciences, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 4 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 40 → 41 (+1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less capital invested
Capital invested by funds: $366M → $229M (-$138M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$2.41M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.17M |
| 3 |
State Street
Boston,
Massachusetts
|
+$374K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$189K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$245K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$235K |
| 3 |
Goldman Sachs
New York
|
-$156K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$112K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$63.2K |
EVLO Hedge Fund Activity: Q1 2019 in Review
41 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q1 2019, worth a combined $229M — down 38% from $366M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EVLO positions and 4 closed out — a net gain of 1 holder — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Sectoral Asset Management, adding an estimated $2.41M. The largest seller was BlackRock, cutting an estimated $245K.
- 41 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q1 2019, up from 40 in Q4 2018.
- Funds reported $229M of Evelo Biosciences, Inc. Common Stock stock for Q1 2019, down 38% quarter-over-quarter.
- 5 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q1 2019 and 4 closed out, a net change of +1 holder.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q1 2019 was Sectoral Asset Management, an estimated $2.41M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q1 2019 was BlackRock, an estimated $245K sold.
Based on aggregated 13F filings for Q1 2019.